ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2020 ◽
Vol 20
◽
pp. S267-S268
Gilles Salles
◽
Johannes Duell
◽
Eva González-Barca
◽
Wojciech Jurczak
◽
Anna Marina Liberati
◽
...